Log In
Print this Print this

Movantik, Naloxegol (Moventig) (formerly NKTR-118)

  Manage Alerts
Collapse Summary General Information
Company Nektar Therapeutics
DescriptionPEGylated form of naloxol, a peripheral mu opioid receptor (OPRM1; MOR) antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionOpioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC)
Regulatory Designation U.S. - Undisclosed Review (Treat opioid-induced constipation (OIC));
EU - Standard Review (Treat opioid-induced constipation (OIC));
Canada - Standard Review (Treat opioid-induced constipation (OIC))
PartnerAstraZeneca plc;
Daiichi Sankyo Co. Ltd.;
Kyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today